Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA user fees

This article was originally published in The Tan Sheet

Executive Summary

NDMA writes Senate Appropriations/agriculture subcommittee Chair Dale Bumpers (D-Ark.) on Aug. 9 urging him to support full funding for FDA and "oppose the Senate amendment adding $163 mil. in new user fees to reduce the deficit" that was adopted in July. A similar request was made by the Pharmaceutical Research and Manufacturers of America ("The Tan Sheet" Aug. 15, In Brief). NDMA also railed against the "substitution of general purpose user fees for regular appropriations because it would reduce the level of basic appropriations for FDA salaries and expenses to about $95 mil. below the estimated threshold" for FY 1995. NDMA urged members of the conference committee to "agree on the House-approved level of $835 mil. in basic appropriations and oppose any efforts to substitute user fees for regular appropriations"

You may also be interested in...



People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

PS083137

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel